BTK and B-cell chronic lymphocytic leukemia: Considering its claimed potency and selectivity toward BTK (8), TL-895 is a promising therapeutic option for chronic lymphocytic leukemia with the potential to improve safety over existing BTK inhibitors and induce more on-target, durable responses (15).